Elexacaftor-tezacaftor-ivacaftor, widely used since the Food and Drug Administration’s release in October 2019, increases CFTR function for those with at least 1 F508del CFTR mutation, which is 86% of the US population with CF [45]. This evidence concerns the gene CFTR and cystic fibrosis.